% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • chimakot chimakot May 4, 2013 3:24 PM Flag

    ....has a solid chance of approval in the back half of the year,"......

    I thought approval would not happen until 2014, am I wrong or is Cramer wrong? TIA

    "I think their drug Tedizolid, for MRSA skin infections, has a solid chance for approval in the back half of the year," Cramer said. "The company has $100 million in cash to fund commercial operations, and Tedizolid could garner peak sales of $800 million. So I favor the risk reward here, but please use price limits. Biotech investing is tricky, especially within these tiny micro caps."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies